Martinez Juliana A, Xiao Qing, Zakarian Armen, Miller Brian G
Department of Chemistry and Biochemistry, Florida State University , Tallahassee, Florida 32303, United States.
Department of Chemistry and Biochemistry, University of California, Santa Barbara , Santa Barbara, California 93106, United States.
Biochemistry. 2017 Jun 20;56(24):3150-3157. doi: 10.1021/acs.biochem.7b00377. Epub 2017 Jun 7.
The glucokinase regulatory protein (GKRP) plays an essential role in glucose homeostasis by acting as a competitive inhibitor of glucokinase (GCK) and triggering its localization to the hepatocyte nucleus upon glucose deprivation. Metabolites such as fructose 6-phosphate and sorbitol 6-phosphate promote assembly of the GCK-GKRP complex, whereas fructose 1-phosphate and functionalized piperazines with potent in vivo antidiabetic activity disrupt the complex. Here, we establish the molecular basis by which these natural and synthetic ligands modulate the GCK-GKRP interaction. We demonstrate that a small-molecule disruptor of the protein-protein interaction utilizes a two-step conformational selection mechanism to associate with a rare GKRP conformation constituting 3% of the total population. Conformational heterogeneity of GKRP is localized to the N-terminus and deleting this region eliminates the ability of sorbitol 6-phosphate to promote the GCK-GKRP interaction. Stabilizing ligands favor an extended N-terminus, which sterically positions two arginine residues for optimal Coulombic interaction with a pair of carboxylate side chains from GCK. Conversely, disruptors promote a more compact N-terminus in which an interfacial arginine residue is stabilized in an unproductive orientation through a cation-π interaction with tyrosine 75. Eliminating the ability to sample this binding impaired conformation enhances the intrinsic inhibitory activity of GKRP. Elucidating the molecular basis of ligand-mediated control over the GCK-GKRP interaction is expected to impact the development and future refinement of therapeutic agents for diabetes and cardiovascular disease, which result from improper GKRP regulation of GCK.
葡萄糖激酶调节蛋白(GKRP)通过作为葡萄糖激酶(GCK)的竞争性抑制剂并在葡萄糖缺乏时触发其定位于肝细胞核,在葡萄糖稳态中发挥重要作用。代谢物如6-磷酸果糖和6-磷酸山梨醇促进GCK-GKRP复合物的组装,而1-磷酸果糖和具有强大体内抗糖尿病活性的功能化哌嗪则破坏该复合物。在这里,我们确定了这些天然和合成配体调节GCK-GKRP相互作用的分子基础。我们证明,一种蛋白质-蛋白质相互作用的小分子破坏剂利用两步构象选择机制与占总群体3%的罕见GKRP构象结合。GKRP的构象异质性定位于N端,删除该区域会消除6-磷酸山梨醇促进GCK-GKRP相互作用的能力。稳定配体有利于延伸的N端,该N端在空间上定位两个精氨酸残基,以便与GCK的一对羧酸盐侧链进行最佳库仑相互作用。相反,破坏剂促进更紧凑的N端,其中一个界面精氨酸残基通过与酪氨酸75的阳离子-π相互作用以非生产性方向稳定。消除采样这种结合受损构象的能力会增强GKRP的内在抑制活性。阐明配体介导的对GCK-GKRP相互作用的控制的分子基础有望影响糖尿病和心血管疾病治疗药物的开发和未来改进,这些疾病是由GKRP对GCK的不当调节引起的。